National Cardiovascular Disease Laboratory Launched in Shenzhen, China

A New National Laboratory for Cardiovascular Diseases in Shenzhen

A national laboratory dedicated to cardiovascular diseases has been established in Shenzhen, China. This collaborative effort between Baheal Pharma Group and two hospitals affiliated with the Chinese Academy of Medical Sciences, Fuwai Hospital and Fuwai Shenzhen Hospital, aims to accelerate the industrialization of innovative advancements in the field.

Disease warning and prediction: This involves developing methods to identify individuals at risk of developing cardiovascular diseases, allowing for early intervention and prevention.

The laboratory will strive to identify new drug targets and develop novel therapies for cardiovascular diseases.

This focus area aims to promote the development of innovative medical devices for the diagnosis and treatment of cardiovascular diseases within China.

Baheal Pharma Group emphasizes the laboratory's comprehensive approach, encompassing all stages from research to industrial implementation. This integrated system is designed to facilitate the swift translation of research findings into practical applications.

The establishment of this laboratory comes at a crucial time, as the prevalence of cardiovascular diseases in China continues to rise. According to a report from the National Center for Cardiovascular Diseases, the number of patients in China has reached a staggering 330 million.

Beyond its research focus, the laboratory will also provide support and resources for the development of cardiovascular disease diagnosis and treatment. This comprehensive approach aims to improve the overall management of cardiovascular diseases in China, ultimately contributing to better patient outcomes.